
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
An interview with Dr. Albert Edwards offers his take on how pilot testing can ease the implementation of eCTD.
Pilot Test Your eCTD Software






